ASCO26: Toni Choueiri, MD, KEYNOTE-654 - Takeaways - MDSpire

ASCO26: Toni Choueiri, MD, KEYNOTE-654

Data highlights limitations of ctDNA assay used to predict outcomes in participants with renal cell carcinoma treated with adjuvant pembrolizumab in the KEYNOTE-564 trial. Dana-Farber Cancer Institute's Dr. Toni Choueiri explains that ctDNA+ was associated with worse disease-free outcomes, but sensitivity was low.

  • July 1, 2026

Share

  • 1

    The ctDNA assay used in the KEYNOTE-564 trial has limitations in predicting outcomes for renal cell carcinoma.

  • 2

    Dr. Toni Choueiri from Dana-Farber Cancer Institute discussed the association of ctDNA+ with worse disease-free outcomes.

  • 3

    The sensitivity of the ctDNA assay in predicting outcomes was found to be low.

  • 4

    Participants in the KEYNOTE-564 trial were treated with adjuvant pembrolizumab.

  • 5

    The findings highlight the challenges in using ctDNA as a biomarker for renal cell carcinoma outcomes.

Original Source(s)

ASCO26: Toni Choueiri, MD, KEYNOTE-654

  • July 1, 2026

Related Content

Bioinformatics Investigations Uncover the Involvement of RIPK1 in Clear Cell Renal Cell Carcinoma

Clear cell renal cell carcinoma presenting as isolated symptomatic lumbar vertebral metastasis: a case report

Correction: Strategies for Combination Therapy to Address Resistance to Immune Checkpoint Inhibitors